ArticleEuropean journal of pediatrics2026
Clinical utility of a novel index for predicting metabolic dysfunction-associated steatotic liver disease risk in children.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral adiposity is a key driver of metabolic dysfunction. Although indices such as the Visceral Adiposity Index (VAI) are widely used in adults, no standardized, practical tool exists for assessing visceral fat accumulation in children and adolescents. We aimed to develop a simple, clinically applicable model for the early identification of metabolic dysfunction-associated steatotic liver disease (MASLD) in pediatric obesity. We retrospectively analyzed 219 children and adolescents with obesity. Clinical, anthropometric, laboratory, and imaging data were collected. Hepatosteatosis and its severity were assessed by ultrasonography. Multivariable logistic regression models were constructed to identify independent predictors and to develop a parsimonious prediction model. The mean age was 13.34 ± 3.17 years, and 63% were female. Anthropometric measures (body weight, BMI, waist circumference, and waist-to-height ratio) increased across steatosis grades. Metabolic markers, including insulin, AST, ALT, and HOMA-IR, showed a progressive increase with disease severity. A parsimonious model (Model 1), incorporating only age, sex, BMI SDS, and waist circumference SDS, demonstrated robust discriminative performance and outperformed HOMA-IR and adult-derived indices (VAI and TyG), which showed limited predictive utility in this population.
conclusionWe present a novel, anthropometry-based model that accurately identifies MASLD in children with obesity using readily available clinical parameters. This pragmatic approach enables early risk stratification and may facilitate implementation in routine pediatric practice. WHAT IS KNOWN: • Visceral adiposity is closely associated with metabolic dysfunction and increased cardiometabolic risk in children with obesity. • Anthropometric and biochemical markers have been proposed as noninvasive tools for predicting metabolic associated steatotic liver disease (MASLD) in pediatric populations. WHAT IS NEW: • Visceral adiposity-related indices were significantly associated with the presence and severity of MASLD in children and adolescents with obesity. • The study highlights the potential utility of simple anthropometric and metabolic markers in the early identification of pediatric patients at higher risk for MASLD.
Indexed as
Identifiers
42223658What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.